2020
Observation with or without late radiotherapy is equivalent to early radiotherapy in high-risk prostate cancer after radical prostatectomy: A SEER-Medicare analysis on trends, survival outcomes, and complications
Kwon Y, Wang W, Srivastava A, Jang T, Singer E, Parikh R, Kim W, Kim I. Observation with or without late radiotherapy is equivalent to early radiotherapy in high-risk prostate cancer after radical prostatectomy: A SEER-Medicare analysis on trends, survival outcomes, and complications. Prostate International 2020, 9: 82-89. PMID: 34386450, PMCID: PMC8322776, DOI: 10.1016/j.prnil.2020.10.002.Peer-Reviewed Original ResearchHigh-risk prostate cancerLate radiotherapyDRT groupProstate cancerSurvival outcomesHigh-risk pathologic featuresMultivariable Cox regression modelsCancer-specific survival outcomesFive-year overallPost-RP radiotherapySEER-Medicare analysisMonths of surgeryWorse survival outcomesKaplan-Meier analysisCox regression modelProportion of menCochran-Armitage trend testEarly radiotherapyPathologic featuresRegression modelsStudy cohortERT groupRadical prostatectomyClinical trialsRadiation toxicity
2011
Pathological findings following radical prostatectomy in patients who are candidates for active surveillance: impact of varying PSA levels.
Kang D, Jang T, Jeong J, Choi E, Johnson K, Lee D, Kim W, Kim I. Pathological findings following radical prostatectomy in patients who are candidates for active surveillance: impact of varying PSA levels. Asian Journal Of Andrology 2011, 13: 838-41. PMID: 21785442, PMCID: PMC3739560, DOI: 10.1038/aja.2011.54.Peer-Reviewed Original ResearchConceptsActive surveillance criteriaActive surveillancePSA levelsSurveillance criteriaRadical prostatectomyLow-risk prostate cancerProstate-specific antigen levelRate of upstagingRisk of upstagingActive surveillance protocolsAcceptable treatment optionRisk of upgradingProportion of menNational Cancer InstituteCalifornia San FranciscoRisk of menContext of PSAPathological findingsAntigen levelsBiochemical recurrencePathological characteristicsSurveillance protocolTreatment optionsProstate cancerInclusion criteria